About Synlogic Therapeutics
Synlogic Therapeutics is a company based in Cambridge (United States) founded in 2013 by James J Collins. Synlogic Therapeutics has raised $34.4 million across 9 funding rounds from investors including Gates Foundation, HHS and Orbimed. The company has 1 employees as of December 31, 2024. Synlogic Therapeutics offers products and services including Synthetic Biotics. Synlogic Therapeutics operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Amyris and Rhythm Pharmaceuticals, among others.
- Headquarter Cambridge, United States
- Employees 1 as on 31 Dec, 2024
- Founders James J Collins
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Synlogic, Inc.
-
Annual Revenue
$8 K (USD)-99.76as on Dec 31, 2024
-
Net Profit
-$23.36 M (USD)61.88as on Dec 31, 2024
-
EBITDA
-$14.48 M (USD)70.96as on Dec 31, 2024
-
Total Equity Funding
$34.4 M (USD)
in 9 rounds
-
Latest Funding Round
$80 M (USD), Post-IPO
Jun 18, 2019
-
Investors
Gates Foundation
& 11 more
-
Employee Count
1
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Synlogic Therapeutics
Synlogic Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SYBX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Synlogic Therapeutics
Synlogic Therapeutics offers a comprehensive portfolio of products and services, including Synthetic Biotics.
Engineered microbes to treat metabolic diseases like PKU.
People of Synlogic Therapeutics
Unlock access to complete
Funding Insights of Synlogic Therapeutics
Synlogic Therapeutics has successfully raised a total of $34.4M across 9 strategic funding rounds. The most recent funding activity was a Post-IPO round of $80 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Synlogic Therapeutics
Synlogic Therapeutics has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Gates Foundation, HHS and Orbimed.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Diversified investment, VC & financial advisory firm
|
Locked | Locked | Locked | |
|
Private equity and hedge fund investments in healthcare are managed.
|
Locked | Locked | Locked | |
|
VC Firm investing in geographies such as the US
|
Locked | Locked | Locked |
Investor details for Synlogic Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Synlogic Therapeutics
Investment portfolio details for Synlogic Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Synlogic Therapeutics
Detailed financials for Synlogic Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Synlogic Therapeutics Comparisons
Peer comparison for Synlogic Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Synlogic Therapeutics
Synlogic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Amyris and Rhythm Pharmaceuticals, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Developer of renewable products for industrial solutions
|
|
| Locked | Locked | Locked |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
|
|
| Locked | Locked | Locked |
Developer of drugs for treating rare and autoimmune diseases
|
Detailed competitors of Synlogic Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Synlogic Therapeutics
Complete news archive for Synlogic Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synlogic Therapeutics
Synlogic Therapeutics was founded in 2013.
Synlogic Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Synlogic Therapeutics is a funded company, having raised a total of $34.4M across 9 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Synlogic Therapeutics is 1.
Annual revenue of Synlogic Therapeutics is $8K as on Dec 31, 2024.
Synlogic Therapeutics was founded in 2013 in Cambridge, Massachusetts, within the biotechnology sector. A proprietary platform is employed to engineer microbes for drug production, targeting urea cycle disorders and phenylketonuria. Standardized interchangeable parts and gene-circuit controls are integrated to design synthetic biology solutions. Microbes are transformed into symbiotic living therapeutics that respond to pathophysiological signals in the human body, facilitating targeted treatments.
Synlogic Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Synlogic Therapeutics offers Synthetic Biotics.
Yes, Synlogic Therapeutics is publicly traded on NASDAQ under the ticker symbol SYBX.
Synlogic Therapeutics has 12 investors. Key investors include Gates Foundation, HHS, Orbimed, Atlas Venture, and Perceptive Advisors.
The ticker symbol of Synlogic Therapeutics is SYBX on NASDAQ.